Skip to main content
. 2014 Dec 15;5(1):72–86.

Figure 5.

Figure 5

Changes in downstream signaling molecules after TKI258 treatment in LoVo and HT-29 cells. KRAS mutant LoVo and BRAF mutant HT-29 cells were treated with 1 μM TKI258 in vitro to evaluate the time-dependent effect on downstream signaling molecules by using western-blotting analysis. PI3K-AKT and RAS-RAF-ERK pathways appeared to be inhibited by TKI258 in LoVo cells, but the PI3K-AKT pathway was not inhibited in HT-29 cells and, in these cells, the RAS-RAF-ERK pathway appeared to be activated. (24 hour treatment data not shown, since cells were damaged due to long serum free status).